How IL-9-secreting T cells can kill tumors more effectively
Official title: Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells
Funded at Methodist Hospital Research Institute · NIH-10892825 · Data updated 2026-11-12
This study is looking at how a special type of immune cell, called IL-9-secreting CD8+ Tc9 cells, can help fight tumors in a new way, and it aims to find better treatments for cancer by using these cells to make tumors die more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $449,554 |
| NIH project number | 5R01CA282099-02 |
| Project ID | NIH-10892825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with tumors that may respond to treatments involving immune cell therapies, particularly those involving CD8+ T cells.
✕Less likely to help
Patients with tumors that do not express the necessary markers for Tc9 cell targeting or those who are not eligible for immune cell therapies may not benefit from this research.
What this research studies
This research investigates the role of a specific type of immune cell, known as IL-9-secreting CD8+ Tc9 cells, in fighting tumors. The researchers have found that these Tc9 cells can induce a unique form of cell death in tumors called pyroptosis, which is more effective than the traditional methods used by other immune cells. By understanding the mechanisms behind this enhanced tumor-killing ability, the research aims to develop new therapeutic strategies that harness the power of Tc9 cells to improve cancer treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that utilize the body's immune system to eliminate tumors.
How similar studies have gone: Other research has shown promising results with similar immune cell therapies, indicating that this approach has potential for success.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Yi, Qing — Methodist Hospital Research Institute
- Study coordinator: Yi, Qing
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Cefazolin Inoculum Effect and MSSA Bacteremia: A Rapid Test to Guide Therapy
A study to understand how a high bacterial load affects cefazolin treatment for serious Staphylococcus aureus infections and to test a quick lab method that helps doctors choose the best antibiotic.
-
Cefazolin Inoculum Effect: How this test could improve care for MSSA bloodstream infections
This project tests a quick lab test to find a specific cefazolin resistance pattern in MSSA blood infections so doctors can choose safer, more effective treatment.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
How brain connections guide visual choices in ADHD
A research study aims to understand how specific brain pathways help people with ADHD make visual decisions, using non-invasive methods in primates.
-
Why some Klebsiella pneumoniae infections resist key carbapenem antibiotics
This project looks at why certain Klebsiella pneumoniae infections resist carbapenem antibiotics and how those infections affect adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.